News
CDNA
62.53
+15.14%
8.22
Thursday's ETF Movers: ARKG, TAN
NASDAQ · 3h ago
CareDx rises 9.1%
TipRanks · 4h ago
CareDx Is Maintained at Buy by BTIG
Dow Jones · 10h ago
Zacks.com featured highlights include CareDx, Ciena, Celestica, Materion and MACOM Technology Solutions
NASDAQ · 11h ago
Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently
Benzinga · 1d ago
Craig-Hallum sees potential for confusion after CMS fee schedule
TipRanks · 2d ago
Weekly Report: what happened at CDNA last week (0914-0918)?
Weekly Report · 3d ago
10 mid-cap healthcare stocks with the strongest momentum grades
Seeking Alpha · 09/17 14:10
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
Seeking Alpha · 09/17 13:45
Weekly Report: what happened at CDNA last week (0907-0911)?
Weekly Report · 09/14 09:18
CareDx management to meet with BTIG
TipRanks · 09/11 16:30
Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks
NASDAQ · 09/09 12:41
Weekly Report: what happened at CDNA last week (0831-0904)?
Weekly Report · 09/07 09:16
CareDx Initiated at Buy by Canaccord Genuity
Dow Jones · 09/02 15:50
CareDx Price Target Announced at $65.00/Share by Canaccord Genuity
Dow Jones · 09/02 15:50
Canaccord Genuity Initiates Coverage On CareDx with Buy Rating, Announces Price Target of $65
Benzinga · 09/02 15:40
CareDx initiated with a Buy at Canaccord
TipRanks · 09/02 09:55
Weekly Report: what happened at CDNA last week (0824-0828)?
Weekly Report · 08/31 09:18
CareDx (CDNA) is a Great Momentum Stock: Should You Buy?
NASDAQ · 08/27 16:00
Biotech Stocks At 52-Week Highs - GENB +15%, BDSX +10%, CDNA +6%, CPIX +10%, CRDL +7%
NASDAQ · 08/26 08:33
More
Webull provides a variety of real-time CDNA stock news. You can receive the latest news about Caredx through multiple platforms. This information may help you make smarter investment decisions.
About CDNA
CareDx, Inc. is a precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, the Company is focused on improving patient outcomes. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; digital health technologies; and patient solutions that support care before and after transplant. The Company also provides genomic-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.